DSHNHL 2006-1A (AATT)
General information and documents for the clinical trial DSHNHL 2006-1A / AATT.
Autologous or allogeneic transplantation following conventional chemotherapy in younger patients (18-60 yrs.) with mature (peripheral) T-cell lymphoma (Acronym: AATT)
The aim is to investigate whether the event-free survival of patients with primary diagnosis of mature (peripheral) T-cell lymphoma can be improved by allogeneic hematopoietic stem cell transplantation after conditioning with FBC compared to autologous peripheral blood stem cell transplantation after high dose therapy with BEAM. Conventional treatment before high dose therapy will be the same for both treatment arms (4 cycles of CHOEP-14 followed by one cycle of DHAP).
The aim is to investigate whether the event-free survival of patients with primary diagnosis of mature (peripheral) T-cell lymphoma can be improved by allogeneic hematopoietic stem cell transplantation after conditioning with FBC compared to autologous peripheral blood stem cell transplantation after high dose therapy with BEAM. Conventional treatment before high dose therapy will be the same for both treatment arms (4 cycles of CHOEP-14 followed by one cycle of DHAP).
Responsible for this study:
Competence Centre Hamburg
Asklepios Hospital St. Georg
Department for Haematology and Stem Cell Transplantation
Lohmuehlenstr. 5
20099 Hamburg
Germany
Phone: +49 (0) 40-18 18 85-2005
Fax: +49 (0) 40-18 18 85-4226
General Information
Publicly available documents
Synopsis (15 kB, 2 pages)Navigation
Clinical Trials & Study Groups
Foerderer, Partner und Zertifikate
,
